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ABSTRACT
In recent years, evidence has emerged for the
existence of many diverse types of RNA, which
play roles in a wide range of biological processes
in all kingdoms of life. These molecules generally
do not, however, act in isolation, and identifying
which proteins partner with RNA is a major chal-
lenge. Many methods, in vivo and in vitro, have
been used to address this question, including
combinatorial or high-throughput approaches,
such as systematic evolution of ligands, cross-
linking and immunoprecipitation and RNA immuno-
precipitation combined with deep sequencing.
However, most of these methods are not trivial to
pursue and often require substantial optimization
before results can be achieved. Here, we demon-
strate a simple technique that allows one to
screen proteins for RNA-binding properties in a
gel-shift experiment and can be easily imple-
mented in any laboratory. This assay should be a
useful first-pass tool for assessing whether a
protein has RNA- or DNA-binding properties, prior
to committing resources to more complex
procedures.
INTRODUCTION
In recent years, interest in RNA has been consistently
increasing as our understanding of the enormous diversity
of RNA biology has developed. Besides the well-studied
small nuclear and nucleolar RNA, ribosomal RNA and
transfer RNA species, a plethora of other non-coding
RNAs have emerged as important players in biological
processes, including small interfering RNAs (1), micro
RNAs (2,3) and long intergenic non-coding RNAs (4,5),
underscoring the imperative for deﬁning the biochemical
functions of these versatile molecules.
Most RNA molecules act in concert with proteins and a
variety of experimental strategies have been developed to
deﬁne the RNA-binding properties of such proteins.
Biophysical approaches, such as ﬂuorescence anisotropy
(6), surface plasmon resonance (7) and isothermal titration
calorimetry (8,9) can provide detailed insight into inter-
actions, kinetics and/or thermodynamics of protein–RNA
binding, whereas NMR spectroscopy and X-ray crystal-
lography allow the structural basis for RNA recognition
to be deﬁned. These approaches rely, however, on a prior
knowledge of the target RNA sequence. Combinatorial
methods, either in vivo or in vitro based, can allow the
researcher to deﬁne the sequence preferences of a chosen
RNA-binding protein. Systematic evolution of ligands by
exponential enrichment (SELEX) is a well-established
method for assessing the sequence preferences of a
puriﬁed protein in vitro, and methods such as RNA-
binding protein immunoprecipitation-microarray proﬁling
(RIP-Chip) (10–12), RNA-binding protein immunopre-
cipitation coupled with high-throughput sequencing
(RIP-seq) (13), in vivo cross-linking and immuno-
precipitation (CLIP) (14,15) and its derivatives are high-
throughput methods that provide a snapshot of the
RNA-binding activity of a protein in a cellular context.
These combinatorial methods, while powerful, can require
substantial optimization before they yield reliable data
and are often not trivial for an inexperienced laboratory
to set up. Furthermore, while the cost of deep-sequencing
analysis is declining, a considerable ﬁnancial outlay is still
required and can add to the activation barrier for a po-
tential user.
Homopolymer pull-down experiments (in which
homomeric ribopolymers such as polyA are attached to
agarose or Sepharose beads and used to capture a protein
of interest) and electrophoretic mobility shift assays
(EMSAs) offer much simpler options for detecting
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RNA-binding activity in a target protein. A disadvantage
of the former approach, however, is that only a very small
range of RNA sequence space can be probed. Similarly, in
a typical EMSA, one must choose the RNA sequence of
interest, limiting the screening potential of this approach.
In previous work, we sought to create double-stranded
DNA (dsDNA) sequences of maximum sequence diver-
sity, reasoning that such sequences could be used as
EMSA probes to screen new proteins for DNA-binding
activity. We designed an algorithm that allowed the con-
struction of a dsDNA sequence containing all possible n-
base pair sequences in the shortest possible sequence (16).
For example, we showed mathematically that 516 bp is the
shortest theoretically possible length for an oligonucleo-
tide that contains all 1024 5-bp combinations. We went on
to show that such sequences of minimal length exist, and
we constructed six overlapping 100-bp oligonucleotides
(termed Pentaprobes) that contained all possible 5-bp se-
quences, based on the observation that many eukaryotic
DNA-binding proteins recognize short sequence motifs.
These oligonucleotides have proven to be a useful ﬁrst-
pass screening tool for the detection of DNA-binding
activity.
In this work, we extend the Pentaprobe concept to
single-stranded RNA (ssRNA). A substantial body of
structural work has emerged in the last decade that
provides insight into the molecular mechanisms by
which proteins recognize ssRNA (17,18). A survey of the
literature reveals that a similar pattern exists to that
observed for dsDNA-binding proteins, in that many
RNA-binding domains recognize sequences of 4–5 nt
in length [Pumilio repeat domains are a notable exception
(19,20)], with greater speciﬁcity being achieved through
the use of tandem repeats of these recognition domains
(18,21–23). Based on that observation, we have created
vectors that allow the transcription of DNA
Pentaprobes from a T7 promoter, yielding RNA
Pentaprobes; the RNA-binding activity of a protein of
interest can therefore be assessed in a straightforward
way in an EMSA. These probes may prove to be a
useful tool for laboratories seeking an initial indication
of whether a target protein might act by recognizing
ssRNA without the complication and expense associated
with combinatorial screening or CLIP-type experiments.
MATERIALS AND METHODS
Pentaprobe design and construction
A sequence of minimum theoretical length (516 bp)
containing every possible 5-nt long motif was designed
computationally (16) and created as six double stranded,
100-bp long, overlapping sequences we termed Pen-
taprobes (PPs). These oligonucleotides were synthesized
(Sigma-Aldrich) as 12 ssDNAs (PP1–PP12; Sup-
plementary Figure S1). PP1 is complementary to PP7,
PP2–PP8 and so on.
To enable production of ssRNA Pentaprobes by in vitro
transcription, PP 1–6 were each annealed with the com-
plementary PP and each double-stranded probe was
inserted into the pcDNA3.1 plasmid downstream of a
T7 promoter site. Ligation was performed in a blunt
end, bidirectional manner and clones selected to obtain
12 plasmids, each capable of transcribing one of the 12
PP sequences as ssRNA.
Other plasmids
pGEX2T vectors containing ZRANB2 F132N (residues
1–41), ZRANB2 F2 (residues 65–95) and a pGEX6P
vector encoding ZRANB2 F1232D (residues 1–95) were
described previously (24).
hnRNP F qRRM12, qRRM1 F120A-Y180A, Fox-1
RRM and Fox-1 RRM F160A (25,26), each cloned into
a pET28 vector, were generously donated by Frederic
Allain’s laboratory (ETH, Zurich).
ZNF180ZF (residues 344–691) was generously donated
by Seth Frietze, University of Southern California and
cloned into a pMalp2X vector.
Lysozyme was purchased from Biomatik.
A pET11a vector containing GATA1 C-terminal zinc
ﬁnger [residues 237–318 of human GATA1(27)] was gen-
erously donated by Jacqui Matthews, University of
Sydney, Australia.
A pGEX2T vector containing the transcriptional
co-regulator LMO2-LDB1LID (the complete coding
sequence of mouse LMO2 fused to a 40 residue region
of ldb1) (28) was generously donated by Jacqui
Matthews, University of Sydney, Australia.
Probe preparation
Synthetic ssDNA probes were 50-end labeled with [g-32P]
ATP (PerkinElmer), by adding 5 pmol oligonucleotide,
30 mCi [g-32P] ATP, 1 ml 10 buffer (70mM Tris–Cl,
pH 7.6, 10mM MgCl2 and 5mM DTT) and 1 ml T4
polynucleotide kinase into 10 ml total volume and
incubating the reaction for 30min at 37C. Double-
stranded oligonucleotides were prepared by mixing
labeled oligonucleotide (20 pmol) with the unlabeled com-
plementary oligonucleotide in a 1:4 molar ratio in 50 ml of
buffer (10mM Tris–Cl, pH 8.0, 50mM NaCl and 1mM
EDTA), heating for 1min at 95C and then annealing by
cooling slowly to room temperature. Unincorporated
[g-32P] ATP was removed from all reactions by
Sephadex G-25 Quick SpinTM columns and labeled
probes were stored at 20C until needed.
Single-stranded RNA Pentaprobes were produced by
linearizing the pcDNA3.1 plasmid, containing the
Pentaprobe of interest, with ApaI and ﬁlling the resulting
30 overhang with DNA polymerase I large (Klenow)
fragment (New England Biolabs). ApaI was used due to
its proximity to the 30-end of the inserted Pentaprobe to
terminate the transcription reaction after the insertion site
and thus to prevent the addition of nucleotides to the
constant region. Transcription was carried out using an
in vitro transcription kit (RiboMAXTM Large Scale RNA
production system-T7, Promega) in the presence of [a-32P]
UTP (10mCiml1) and subsequently the probes were gel
puriﬁed under denaturing conditions by incubation at
95C for 2min followed by gel electrophoresis on a
pre-equilibrated 6% Urea–TBE gel (InvitrogenTM); this
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step eliminated truncations and unincorporated single nu-
cleotides. Probes were stored at 20C until needed.
Protein preparation
Plasmids containing hnRNP F qRRM12, hnRNP F
qRRM1 F120A-Y180A, Fox-1 RRM, Fox-1 RRM
F160A were transformed into Escherichia coli (BL21) and
incubated in LB media containing Kanamycin at 37C
until OD600 of 0.6 was reached. Protein expression was
induced using 0.4mM IPTG and bacteria were cultivated
at 20C over night. Cells were harvested by centrifugation
(5000 rpm, 30min, 4C) and resuspended in lysis buffer
[50 mM Na2HPO4, pH 8, 10mM imidazole, 0.5mM
PMSF and 200mM NaCl (Fox-1) or 1M NaCl
(hnRNP F)]. In each case, over-expressed protein was
released from the cells by gentle sonication and the
soluble fraction was separated from the insoluble fraction
through centrifugation (10 000 rpm, 30min, 4C). The
soluble fraction was incubated with Ni-NTA Agarose
beads (InvitrogenTM) and unbound protein and contamin-
ants were removed by washing with lysis buffer. Bound
protein was eluted with an imidazole gradient (50mM
Na2HPO4, pH 8, 100mM NaCl, 20–500mM imidazole).
Plasmids containing ZRANB2 F12 (1–95) were trans-
formed into E. coli (BL21-RIG) cells and incubated in LB
media containing ampicillin and chloramphenicol at 37C.
Protein expression was induced when OD600 reached
0.8–1 by adding 0.2mM IPTG and bacteria were
incubated at 25C for 12–16 h. Cells were harvested by
centrifugation (5000 rpm, 30min, 4C), resuspended in
lysis buffer (50mM Tris–HCl, pH 8.0, 200mM NaCl,
1% TritonX-100, 2mM PMSF, 1.4mM b-
mercaptoethanol, 0.1mgml1 lysozyme, CompleteTM
protease inhibitor (used according to manufacturer in-
structions, Roche) and freeze–thawed once. Following
centrifugation (13 000 rpm, 30min, 4C), the soluble
fraction was bound to glutathione-Sepharose 4B beads
(GE Healthcare) and washed with wash buffer (50mM
Tris–HCl, pH 8.0, 300mM NaCl, 10% glycerol, 2mM
PMSF, 0.1 ml ml1 b-mercaptoethanol) to remove
unbound protein and contaminants. Bound protein was
eluted in a buffer containing 20mM reduced glutathione,
50mM Tris–HCl, pH 8.0, 150mM NaCl, 1mM DTT and
0.005% TritonX-100.
Plasmids containing ZNF180ZF (344–691) were trans-
formed into E. coli (BL21-RIG) cells and incubated in LB
media containing ampicillin at 37C. Protein expression
was induced when OD600 reached 0.6–0.8 by adding
0.5mM IPTG and bacteria were incubated at 37C for
3 h. Cells were harvested by centrifugation (6000 rpm,
20min, 4C), resuspended in lysis buffer [10 mM Tris–
HCl, pH 7.0, 90mM KCl, 1mM MgCl2, 90 mM ZnCl2,
1mM DTT, 0.5mM PMSF, 1M NaCl and CompleteTM
protease inhibitor (used according to manufacturer in-
structions, Roche)] and freeze–thawed twice, followed by
gentle sonication. After DNase I (10 mgml1) and RNase
(5 mgml1) treatment and centrifugation (14 000 rpm,
20min, 4C) the soluble fraction was bound to amylose
resin (New England Biolabs) and washed with wash
buffer [10 mM Tris–HCl, pH 7.0, 90mM KCl, 1mM
MgCl2, 90 mM ZnCl2, 1mM DTT, 0.5mM PMSF, 1M
NaCl, 10% (w/v) glycerol] to remove unbound protein
and contaminants. Bound protein was eluted in a buffer
containing 10mM Tris–HCl, pH 7.0, 90mM KCl, 1mM
MgCl2, 90 mM ZnCl2, 1mM DTT, 0.5mM PMSF, 1M
NaCl, 40mM maltose and 10mM CaCl2.
Plasmids containing GATA1 C-ﬁnger were transformed
into E. coli Rosetta 2 cells and incubated in LB media
containing ampicillin and chloramphenicol at 37C.
Protein expression was induced when OD600 reached
0.6 by adding 0.4mM IPTG and bacteria were
incubated at 37C for 3 h. Cells were harvested by centri-
fugation (5000 rpm, 30min, 4C), resuspended in lysis
buffer (50mM Tris–Cl, pH 8.0, 50mM NaCl, 1% Triton
X-100, 1.4mM PMSF, 1.4mM b-mercaproethanol) and
over-expressed protein was released by gentle sonication.
After centrifugation (14 000 g, 30min), the soluble fraction
was bound to Sepharose beads and washed with buffers
containing increasing amounts of NaCl (50mM HEPES,
pH9, 50mM NaCl, 1mM DTT, with successive washes
containing 200mM of additional NaCl). The eluted frac-
tions were equilibrated to a ﬁnal concentration of 200mM
NaCl and applied to a cation exchange column (Uno S-1,
Bio-Rad). Fractions were eluted with a NaCl gradient
(50mM HEPES, pH 9.0, 1mM DTT, 50mM–1M
NaCl). After determining the purity of the protein by
SDS–PAGE (NuPage, 4–12% Bis–Tris, InvitrogenTM),
the eluted fractions were applied to a gel ﬁltration
column (Superdex 75 16/60, Pharmacia) and eluted in
the elution buffer (50mM HEPES, pH 9.0, 150mM
NaCl, 1mM DTT) [for puriﬁcation see also (29)].
LMO2-LDB1LID was puriﬁed as described in (28,30).
Lysosyme was resuspended in H2O.
Expression and purity of all proteins was monitored by
SDS–PAGE (NuPage, 4–12% Bis–Tris, InvitrogenTM).
Protein concentrations were determined by absorbance
at 280 nm.
RNA-binding assays
Nucleic acid probes (0.1 nM) were incubated with
protein samples in gel shift buffer (10mM MOPS, pH
7.0, 50mM KCl, 5mM MgCl2, 1mM, DTT, 10%
glycerol and 0.03 mg ml1 heparin) at 4C for 30min. For
antibody supershift experiments, 0.1 ml monoclonal
a-GST antibody (mouse) was pre-incubated with the
protein mixture before the addition of nucleic acid
probe. The binding reactions were loaded onto 4–10%
native acrylamide/bisacrylamide gel (19:1) and
electrophoresed in 45mM Tris, 45mM boric acid at
200V for 1–2 h either at 4C or at room temperature.
Gels were visualized on a Phosphor screen with a
Typhoon PhosphoImagerTM (FLA 9000).
RESULTS
Design and production of ssRNA Pentaprobes
We showed previously that a dsDNA sequence of 516 nt
can encode all possible 5-nt motifs when the sequences on
both strands are taken into account (16). In order to
encode all possible motifs in ssRNA, a similar analysis
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shows that a single oligonucleotide with a minimum length
of 1028 nt is required. We chose to approximate this
requirement by using the 12 90–100 nt PP sequences (PP
1–12, Supplementary Figure S1) that we had synthesized
for the dsDNA work. Twelve nucleotides of overlap were
included between successive Pentaprobes to reduce
possible issues with anomalous binding to end sequences.
Each of PP 1–6 was annealed with its reverse complemen-
tary partner sequence (PP 7–12) and individually cloned in
a bidirectional manner into a pcDNA3.1 vector down-
stream of a T7 promoter site, yielding a set of 12 vectors
that each could be used as a template from which to tran-
scribe one of the 12 PP sequences. Prior to transcription,
the vector was linearized with ApaI directly after the
insertion site to prevent the addition of nucleotides to
the constant region and the consequent transcription of
RNA artifacts. Figure 1 shows the important elements
contained in each of these vectors.
To prepare the ssRNA probes, in vitro transcription was
carried out using a standard RiboMAXTM Large Scale
RNA production kit (Promega). Transcription was
carried out in the presence of [a-32P] UTP (10mCiml1)
to allow incorporation of radioactive labeling into the re-
sulting RNA probe. The reaction mixtures were puriﬁed
on a denaturing polyacrylamide gel. Despite the
puriﬁcation step, however, subjecting probes alone to
EMSAs revealed multiple bands in some cases, most
likely reﬂecting the formation of alternative conform-
ations (or multimers) that are in slow exchange on the
timescale of the EMSA (hours). The secondary structures
of each probe were predicted using Mfold (31) and are
shown in Supplementary Figure S2. In an effort to
reduce the multiple banding, we heated one of the
probes that showed multiple bands to denature it and
rapidly cooled it on ice. As shown in Figure 2, this step
signiﬁcantly reduced the occurrence of multiple bands in
EMSAs, thereby improving the overall quality of the
observed band.
Testing the RNA Pentaprobes with known
RNA-binding proteins
To assess the functionality of the RNA Pentaprobes, we
exposed them to well-characterized RNA-binding proteins
containing RNA-binding domains from several structural
classes. The ﬁrst protein tested was ZRANB2, a Ser-Arg
rich (SR)-like protein that contains two RanBP2-type
zinc-ﬁnger domains at its N-terminus. The zinc ﬁngers
of ZRANB2 have been shown to interact with ssRNA in
a sequence-speciﬁc manner, each zinc ﬁnger binding to an
50-AGGUAA-30 motif in its target (24). The function of
Figure 1. Schematic of ssRNA Pentaprobe production. pcDNA3.1 vector containing a dsDNA Pentaprobe sequence under the control of a T7
promoter site is linearized and the in vitro transcribed to produce a ssRNA sequence encoding the Pentaprobe sequence. Highlighted is the ApaI
restriction site (purple), T7 promoter site (pink), the encoded DNA sequence (blue) and the resulting ssRNA probe sequence (blue).
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ZRANB2 is not well understood, but its interaction with
important spliceosomal proteins and ability to alter
splicing of reporter genes suggest a role in pre-mRNA
splicing (32,33).
Figure 3 shows GST-ZRANB2 F12 (1–95) exposed to
dsDNA and ssRNA forms of one of the Pentaprobes. No
retarded bands can be observed when the protein is
incubated with dsDNA Pentaprobe (Figure 3A, lane 4).
Lane 2 shows a positive control, in which the C-terminal
zinc ﬁnger of GATA-1 (a known dsDNA-binding protein)
(34) was mixed with the dsDNA probe and lane 3 shows a
negative control in which GST alone was used to show
that the interaction observed in lane 4 is not mediated by
the GST tag. Figure 3B shows GST-ZRANB2 F12
exposed to one of the 12 ssRNA Pentaprobes, and a
clear shifted band is observed. To verify the speciﬁcity
of the interaction and exclude the possibility of showing
interactions to contaminants, an anti-GST antibody was
used to supershift the complex (lane 7).
We next tested Fox-1, a tissue-speciﬁc regulator of
alternative splicing that contains a single RNA-binding
domain (RNA recognition motif, RRM). This protein rec-
ognizes GCAUG motifs in ssRNA in a sequence-speciﬁc
manner (25). To test binding selective activity in our assay,
the RRM of Fox-1 protein and a point mutant thereof,
F160A, were expressed and puriﬁed using Ni-NTA afﬁnity
chromatography. The point mutant signiﬁcantly reduces
binding afﬁnity to target RNA sequences (25). Figure 4
shows that incubating puriﬁed Fox-1 RRM with different
Pentaprobe RNA sequences results in the appearance of
retarded bands in an EMSA, compared to the probe
alone, demonstrating that Fox-1 binds to the ssRNA
probe. As expected, Fox-1 RRM F160A exhibits weaker
binding activity, with a higher concentration of protein
necessary to give rise to a shifted band and a reduced
retardation of bands in comparison to the wild-type
protein. The difference between wild-type and mutant
was more pronounced with PP4 (Figure 4B).
Examination of the motifs contained in each probe
shows that PP10 contains a GCAUA and other closely
related motifs, which are very similar to the previously
described binding motif of Fox-1. PP4 (Figure 4B), on
the other hand, contains only one such motif, resulting
in different mobilities for the two complexes (Figure 4A
and B). The decreased mobility of the shifted bands
observed at higher protein concentrations suggests that
multiple proteins are binding to a single Pentaprobe.
In order to assess the activity of the whole family of
RNA-Pentaprobes, we carried out REMSAs of Fox-1
with every probe (Supplementary Figure S3). Shifts were
observed for every probe, illustrating the robustness and
sequence diversity contained within the Pentaprobe
system. Some differences were observed in the bands
produced by different Pentaprobes, which most likely
reﬂect differences in the abundance and accessibility of
acceptable target sites. For example, only PP12 contains
the full 5-nt recognition sequence GCAUG, and all other
probes other than PP1, 4 and 8 contain sites that differ
from GCAUG by only one base.
We also tested the quasi-RNA recognition motif
(qRRM) of heterogeneous nuclear ribonucleoprotein F
(hnRNP F), a member of the hnRNP H family that
is involved in the regulation of alternative splicing
and polyadenylation. hnRNP F contains three qRRMs
that bind poly-G sequences (G-tracts) in ssRNA in a
sequence-speciﬁc manner (26). To examine RNA
binding, in our assay, we used a construct containing
hnRNP F qRRM12. Figure 5 shows ssRNA Pentaprobes
PP3 and PP9 exposed to increasing concentrations of
hnRNP qRRM12; retarded bands were detected using
both probes. Note that multiple bands appear in the
PP3 probe-only lane (Figure 5A, Lane 1), which are
probably due to either intermolecular interactions
between probes or the formation of secondary structures.
Binding is observed to both populations of RNA, which
may indicate that the two pools are in equilibrium with
each other.
Testing the RNA Pentaprobes with a putative
RNA-binding protein
Finally, we used ssRNA Pentaprobe to assess the
RNA-binding properties of a protein with no described
RNA-binding activity. ZNF180 is a poorly characterized
multi-zinc-ﬁnger protein that is predicted to contain 12
classical zinc-ﬁnger domains and a KRAB domain. We
expressed and puriﬁed a polypeptide corresponding to
the 12 classical zinc ﬁngers of this protein and tested its
ability to recognize ssRNA by EMSA. Figure 6A shows
that this protein is able to recognize ssRNA, providing a
starting point from which the hypothesis that this protein
Figure 2. Rapid heating and cooling reduces the formation of multiple
conformations in a ssRNA Pentaprobe. 32P-labeled PP3 was subjected
to denaturation and rapid cooling and then analysed on a 4% poly-
acrylamide gel; for comparison, a non-heated probe was also analysed.
Lane 1: probe PP3 pre-denaturation, showing multiple bands that most
likely reﬂect different secondary structure or oligomerization states.
Lane 2: PP3 post denaturation. Structures shown are for illustrative
purposes only.
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Figure 3. Pentaprobe nucleic acid binding by the zinc ﬁngers of ZRANB2. GST, GST-F1, GST-F2 and GST-F12 (15 mM) were incubated with
32P-labeled Pentaprobe in the form of (A) dsDNA and (B) ssRNA. All complexes were analysed on 6% polyacrylamide native gels. (A) ssDNA
mixed with: Lane 1: buffer; Lane 2: GATA 1C-terminal ﬁnger; Lane 3: GST; Lane 4: ZRANB2 GST-F12. (B) ssRNA mixed with: Lane 1: buffer;
Lane 2: GST; Lane 3: ZRANB2 GST-F1; Lane 4: ZRANB2 GST-F2; Lane 5 and 6: decreasing concentrations of ZRANB2 GST-F12; Lane 7:
ZRANB2 GST-F12 in complex with a monoclonal anti-GST antibody; Lane 8: buffer.
A B
Figure 4. Binding of Fox-1 RRM to RNA Pentaprobe sequences. EMSAs show different 32P-labeled RNA Pentaprobes incubated with increasing
concentrations of Fox-1 RRM and the Fox-1 RRM F160A mutant. (A) PP10 mixed with: Lane 1: buffer; Lane 2–5: increasing amounts of Fox-1
RRM (1, 5, 10 and 50 mM); Lane 6–9: increasing amounts of Fox-1 RRM F160A (1, 5, 10 and 50 mM). (B) PP4 mixed with: Lane 1: buffer; Lane 2–
5: increasing amounts of Fox-1 RRM (1, 5, 10 and 50 mM); Lane 6–9: increasing amounts of Fox-1 RRM F160A (1, 5, 10 and 50 mM). All samples
were separated on 4% polyacrylamide gels.
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Figure 6. ZNF180 binding to RNA Pentaprobe sequences. REMSAs showing PP3 incubated with increasing amounts of ZNF180ZF.
(A) Heat-treated PP3 mixed with: Lane 1: buffer; Lane 2–8: increasing amounts of ZNF180 (0.1, 1, 5, 10, 20, 30 and 40 mM). (B) Untreated PP3
mixed with: Lane 1: buffer; Lane 2–8: increasing amounts of ZNF180 (0.1, 0.2, 0.5, 1, 5, 10 and 20 mM). All samples were separated on 4%
polyacrylamide gels.
A B
Figure 5. hnRNP F RRM binding to RNA Pentaprobe sequences. REMSAs showing different Pentaprobes incubated with increasing amounts of
hnRNP F qRRM12. (A) PP3 mixed with: Lane 1: buffer; Lane 2–7: increasing amounts of hnRNP F qRRM12 (0.1, 0.5, 1, 5, 10 and 50 mM).
(B) PP9 mixed with: Lane 1: buffer; Lane 2–4: increasing amounts of hnRNP F qRRM12 (0.5, 5 and 50 mM). All samples were separated on 4%
polyacrylamide gels. Structures shown are for illustrative purposes only.
PAGE 7 OF 11 Nucleic Acids Research, 2012, Vol. 40, No. 14 e105
plays a role in post-transcriptional gene regulation could
be tested using more sophisticated approaches such as
CLIP-seq. Note that the EMSA shown in Figure 6A was
carried out using the probe that had been heat treated in
Figure 2; an EMSA carried out under identical conditions
except that the probe was not pre-treated is shown in
Figure 6B, demonstrating the improvement given by the
denaturation step.
A B C D
Figure 8. Lysozyme, GATA 1C-ﬁnger, Fox 1 and LMO2-LDB1LID binding to RNA Pentaprobe sequences. REMSAs showing different
Pentaprobes incubated with increasing amounts of lysozyme (A), GATA 1C-ﬁnger (B), Fox 1 (C) and LMO2-LDB1LID (D), respectively, in the
presence of 250 mgml1 heparin. (A) PP7 mixed with: Lane 1: buffer; Lane 2–6: increasing amounts of lysozyme (0.1, 0.25, 0.5, 0.75 and 1 mM).
(B) PP7 mixed with: Lane 1: buffer; Lane 2–6: increasing amounts of GATA1 C-ﬁnger (1, 2.5, 5, 7.5 and 10 mM). (C) PP7 mixed with: Lane 1: buffer;
Lane 2–6: increasing amounts of Fox-1 (0.1, 0.25, 0.5, 0.75 and 1 mM). (D) PP2 mixed with: Lane 1: buffer; Lane 2–6: increasing amounts of
LMO2-LDB1LID (0.1, 0.5, 1, 5 and 10 mM); Lane 7: Fox-1 (0.5 mM). All samples were separated on 4% polyacrylamide gels.
A B
Figure 7. The effect of heparin on Pentaprobe EMSAs. EMSAs showing that the binding of GST-ZRANB2 F12 to ssDNA and ssRNA can be
modulated by the addition of heparin. (A) ssDNA Pentaprobe mixed with: Lane 1: buffer; Lane 2–6: increasing amounts of GST-ZRANB2 F1232D
(1, 2, 4, 8 and 16 mM); Lane 7: buffer; Lane 8–11: 15 mM GST-ZRANB2 F1232D in the presence of 0, 2.3, 23 and 230mgml
1 heparin. (B) Internally
32P labeled ssRNA Pentaprobe mixed with: Lane 1–2: buffer; Lane 3–6: increasing amounts of GST-ZRANB2 F1232D (1.2, 3.5, 11 and 22 mM); Lane
7–9: 11 mM GST-ZRANB2 F1232D in the presence of 2.3, 23 and 230mgml
1 heparin. All samples were separated on a 6% polyacrylamide gel.
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Heparin reduces non-speciﬁc binding to Pentaprobes and
improves clarity of EMSAs
In the case of hnRNP F, Fox-1 and ZNF180ZF, the
addition of increasing amounts of protein results in the
appearance of multiple retarded bands, which correspond
most likely to multiple protein molecules binding to one
molecule of RNA. Similar observations were also made
for ZRANB2 with several of the probes. Such multiple
species can give rise to smearing of the bands that corres-
pond to protein:RNA complexes (Figure 4B, lane 3),
reducing the clarity of the assay. We therefore trialed
the addition of heparin to our EMSAs in an effort to
reduce this effect. Heparin, a highly sulfated
glycosaminoglycan that mimics the high negative charge
of nucleic acids, has been shown to act as a DNA or RNA
competitor and has been used widely as such (35). As
shown in Figure 7, the addition of increasing amounts
of heparin to an EMSA using ssDNA or ssRNA
Pentaprobe gradually clariﬁes the gel shift, dampening
the binding of protein to lower afﬁnity partial sites and
resulting in a single, more highly focused band with
improved intensity.
Finally, we addressed the question of whether the Pen-
taprobes can effectively distinguish between genuine and
irrelevant interactions by carrying out REMSAs with
three proteins that are not known to bind RNA in vivo.
We chose lysozyme, the C-terminal zinc ﬁnger of GATA1
(a dsDNA-binding domain) (27) and the LIM-domain
protein LMO2 [a transcriptional co-regulator (36), ex-
pressed as a fusion with a short peptide from its binding
partner ldb1]. The pIs of these proteins are 11.4, 9.0 and
5.7, respectively. As shown in Figure 8, no robust bands
are observed for any of the three proteins, although there
is substantial precipitation in the wells containing high
concentrations of lysozyme. For comparison, the same
range of protein concentrations is shown for Fox-1
(Figure 8D), highlighting that it is straightforward to
distinguish between genuine interactions and non-speciﬁc
aggregation/precipitation. It is worth noting that at lower
heparin concentrations (25 mgml1), more precipitation is
observed for all proteins (including Fox-1) other than
LMO2-ldb1, due most likely to adventitious electrostatic
interactions. The addition of heparin must therefore
represent a balance between the abrogation of such inter-
actions and the possibility that genuine interactions might
be suppressed to below the detection limit of the assay.
The robust bands observed for Fox-1 in the presence of
250 mgml1 heparin argues that genuine interactions are
readily detectable under such conditions.
DISCUSSION
In this study, we have demonstrated that the RNA version
of Pentaprobe provides a straightforward ﬁrst-pass tool to
examine RNA-binding activity in proteins. The relatively
high concentrations of protein that can be used (up to tens
of micromolar) allow for relatively weak interactions to be
detected, as demonstrated by the observation of a shifted
band for the Fox-1 point mutant, which has previously
been shown to have severely impaired RNA-binding
ability. In general, we would suggest an upper limit for
protein concentrations of 1–10mM to reduce the chance of
observing non-physiological interactions or precipita-
tion—although of course this upper limit will differ
substantially for different proteins. Additionally, each
Pentaprobe contains numerous motifs allowing proteins
to bind to high- and low-afﬁnity binding sites simultan-
eously. While this property can provide a measure of the
promiscuity of the protein in question, the presence of
multiple bands reduces the clarity of the gel. The use of
heparin as a competitor can improve the overall appear-
ance of the gel, to a point that, at least in some cases, most
likely represents a 1:1 interaction between protein and
RNA. Similarly, heat treatment of the probe prior to the
experiment (Figure 6A) can improve the overall quality of
the assay by reducing the number of RNA conformers
present during the binding reaction.
Existing data indicate that most ssRNA-binding
proteins are constructed from domains that each display
binding to relatively short RNA sequences, at least
in vitro. We believe that, under our conditions (the
presence of high concentrations of protein and RNA),
the full coverage of 5-nt sequences represented in
Pentaprobe should be sufﬁcient to mediate binding to
most, if not all, of these domains. Pentaprobes can
readily be used to assess not only the binding of full-length
proteins, but also of individual domains, in order to
obtain a rapid assessment of which domains in a
multi-domain protein are more or less important for
RNA recognition. It remains possible, however, that
some proteins that recognize longer target sites, such as
the Pumilio repeat proteins, might exhibit reduced binding
to our probes, given that their recognition sequences are
not fully represented in Pentaprobes.
All of our Pentaprobes exhibit some secondary struc-
ture formation, which in some cases could obstruct the
binding of a protein to RNA or mask a potential
binding site, but so far we have no evidence that the
presence of such structures interferes greatly with our
assay. Indeed, the formation of secondary structure
could even be beneﬁcial, given that some proteins target
RNA secondary structures. An obvious additional appli-
cation in this regard for our method would be the deter-
mination of dsRNA-binding activity. Pentaprobe
sequences can be easily dimerized (PP 1–6 are complemen-
tary to PP 7–12) and run side-by-side with ssRNA probes
to gain an initial impression of whether a target protein
prefers ssRNA or dsRNA. Furthermore, RNAse protec-
tion assays could be attempted, to allow more speciﬁc de-
termination of a binding site comprised in the present
sequence.
We also foresee other possible applications for the
ssRNA Pentaprobe reagent. So far, just highly puriﬁed
protein domains have been tested in our assay to deter-
mine interactions. However, one or even a mixture of
Pentaprobes could be utilized as a broad-spectrum yet
chemically deﬁned bait with which to pull down
RNA-binding proteins from cellular extracts for further
analysis. Finally, these Pentaprobes also constitute a
useful probe from which the RNA-cleaving activity of
RNAse enzymes can be determined; this application has
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been successfully demonstrated in the case of a bacterial
toxin (Vickery Arcus, personal communication).
In conclusion, we have described a reliable method for
the detection of RNA-binding properties in target proteins
that is inexpensive, fast and easy to implement in any
standard life sciences laboratory.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Figures 1–3.
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